Performance and Safety Evaluation of the FHK®-CK Knee Prosthesis

NCT ID: NCT06124482

Last Updated: 2025-06-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-01

Study Completion Date

2028-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The life expectancy worldwide is increasing and leading to an increase of knee arthroplasty. Also, as millions of people around the world are currently living with a Total Knee Arthroplasty (TKA), the need for revision surgery represents a large public health burden. In this context, FH ORTHO company develops FHK®-CK (prosthesis + ancillary equipment) which is a knee prosthesis for complex first intention and revision knee arthroplasty. This new medical device complements the FHK® standard first-line range (CE marked).

The FHK®-CK ancillary equipment were designed by expert knee surgeons and is simple, reliable and reproducible. It allows for maximum versatility while remaining compact.

By completing the FHK® range of first intention prostheses, the FHK®-CK allows the surgeon to be on the same level as the competitors by having a first intention and semi-constrained prosthesis. This prosthetic arsenal allows the surgeon to opt for the best solution for his patient so that he can regain mobility and a satisfactory quality of life. Also, in case of failure of the FHK® first-line prosthesis, it will provide the surgeon and the patient with a simple alternative to prosthesis replacement. As it has been developed in line with the first intention, inter-compatibility between the two systems is possible, which simplifies the surgical procedure and reduces the risks for the patient.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Total Knee Arthroplasty

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Two target populations will be included in this clinical investigation :

* 60 patients requiring primary Total Knee Arthroplasty
* 32 patients requiring revision Knee Arthroplasty.

In this clinical investigation, it was not possible to realize a double-blinding for practical reasons. Nevertheless, a collection of the primary outcome (score KSS) will be realized blindly to the surgeon in charge of the patient by an intervener not involved in the medical care of the patient, who did not participate in the intervention and did not collect the preoperative KSS score.
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Knee replacement

Implantation of FHK-CK prosthesis either for a complex primary arthroplasty or for revision intend

Group Type EXPERIMENTAL

Total Knee arthroplasty

Intervention Type DEVICE

The FHK-CK prosthesis (non CE-Marked, class III) is to be implanted with the use of FHK-CK instruments. The surgery has to be performed in accordance with the practice/guidelines, FHK-CK Instruction For Use (IFU) and surgical techniques documents.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Total Knee arthroplasty

The FHK-CK prosthesis (non CE-Marked, class III) is to be implanted with the use of FHK-CK instruments. The surgery has to be performed in accordance with the practice/guidelines, FHK-CK Instruction For Use (IFU) and surgical techniques documents.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient requiring knee arthroplasty for primary or secondary gonarthrosis:

\* For primary intention arthroplasty: Patient with either
* major axial deviation,
* major peripheral failure or
* bone defect;

\* For prosthesis revision surgery: Patient who have had a failed 1st implantation, with or without bone defects.
* Patient able to understand and answer the questionnaires provided by the protocol;
* Subject affiliated to a health insurance system or is a beneficiary;
* Signed informed consent form (ICF) for participation to the research.

Exclusion Criteria

* Patient with an ongoing acute infection, outside knee to be operated;
* Patient with a mental or neuromuscular disorder that would create an unacceptable risk of prosthetic instability, prosthetic fixation failure or post-operative complications;
* Patient with a known allergy to any of the components of the FHK®-CK implants (Nickel, Cobalt, Chromium);
* Patient with a dependency (drug, alcohol,…) that could affect his/ her ability to comply with the protocol, at the investigator's discretion;
* Patient requiring knee reconstruction;
* Patient with any medically significant findings or significant history that may impact the safety, interpretation of results, and/ or participation of the subject in the clinical trial, as determined by the investigator;
* Patient with an existing knee or hip prosthesis (outside knee to be operated) that may impact the evaluation of the FHK®-CK prosthesis;
* Patient concurrently participating in another clinical trial or who has recently participated in another clinical trial for which the exclusion period has not been completed.
* Vulnerable subjects :

* Pregnant, parturient, or breastfeeding women,
* Subject deprived of liberty, hospitalized without consent or admitted to a health or social establishment for purposes other than that of research,
* Minor,
* Adult under protective supervision (tutorship, curatorship),
* Subject not able to understand the subject information leaflet (e.g. for linguistic or psychiatric reasons) and/or to give informed consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Slb Pharma

OTHER

Sponsor Role collaborator

FH ORTHO

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Privé La Châtaigneraie

Beaumont, , France

Site Status TERMINATED

CHRU de la Cavale Blanche

Brest, , France

Site Status RECRUITING

Hôpital Beaujon AP-HP

Clichy, , France

Site Status RECRUITING

Hôpital Raymond Poincaré AP-HP

Garches, , France

Site Status RECRUITING

CH d'Haguenau

Haguenau, , France

Site Status RECRUITING

Centre Hospitalier Régional Universitaire de Nancy

Nancy, , France

Site Status RECRUITING

Groupe Hospitalier Pitié Salpêtrière AP-HP

Paris, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Carole CARRÉ

Role: CONTACT

06 40 47 16 71 ext. 0033

Delphine KORNER

Role: CONTACT

07 87 86 29 14 ext. 0033

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Frédéric DUBRANA, PhD

Role: primary

Marc-Antoine ROUSSEAU, PhD

Role: primary

Laurent VASTEL, PhD

Role: primary

Michel BRAX, Dr

Role: primary

Didier MAINARD, PhD

Role: primary

0383851782 ext. 0033

Jean-Yves LAZENNEC, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

FH ORTHO SAS Knee Observatory
NCT06207968 NOT_YET_RECRUITING
Active Knee Prosthesis Study
NCT06700668 ACTIVE_NOT_RECRUITING NA